{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cholesterol+Level%2C+High&page=2",
    "query": {
      "condition": "Cholesterol Level, High",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cholesterol+Level%2C+High&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T01:29:29.737Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00972829",
      "title": "Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bronx VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-09",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2009-09-10",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00972829"
    },
    {
      "nct_id": "NCT05763875",
      "title": "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2023-03-15",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05763875"
    },
    {
      "nct_id": "NCT03172611",
      "title": "A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Dietary Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Texas Woman's University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-01-03",
      "completion_date": "2017-03-15",
      "has_results": false,
      "last_update_posted_date": "2017-06-01",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172611"
    },
    {
      "nct_id": "NCT01286311",
      "title": "Tailored Communication to Reduce Cardiovascular Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Coronary Artery Disease",
        "Dyslipidemia",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Direct-to-patient tailored cardiovascular risk message system",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 464,
      "start_date": "2011-01",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2015-02-09",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01286311"
    },
    {
      "nct_id": "NCT00143663",
      "title": "Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Lapaquistat Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2005-09",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2012-05-24",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 47,
      "location_summary": "Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143663"
    },
    {
      "nct_id": "NCT04753606",
      "title": "Randomized Study of Obicetrapib as an Adjunct to Statin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2021-02-18",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04753606"
    },
    {
      "nct_id": "NCT01604824",
      "title": "A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2012-02-22",
      "completion_date": "2017-07-28",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604824"
    },
    {
      "nct_id": "NCT01443650",
      "title": "Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "alirocumab SAR236553 (REGN727)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-06-28",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443650"
    },
    {
      "nct_id": "NCT04941599",
      "title": "2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "2-Hydroxybenzylamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 72,
      "start_date": "2024-02-14",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04941599"
    },
    {
      "nct_id": "NCT02304484",
      "title": "Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 770,
      "start_date": "2014-11-24",
      "completion_date": "2018-03-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-24T01:29:29.737Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Long Beach, California + 21 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304484"
    }
  ]
}